Skip to content
Screener

Alkermes ALKS Interest Expense

Interest Expense at other companies

Jazz Pharmaceuticals logo
Jazz PharmaceuticalsJAZZ
-$39.9M+25.7%
Indivior Pharmaceuticals, Inc. logo
Indivior Pharmaceuticals, Inc.INDV
$7M-41.7%
Harmony Biosciences Holdings, Inc. logo
Harmony Biosciences Holdings, Inc.HRMY
$3.23M-15.7%
Ionis Pharmaceuticals logo
Ionis PharmaceuticalsIONS
$4.62M+12.3%
Rigel Pharmaceuticals logo
Rigel PharmaceuticalsRIGL
$1.43M-22.7%
Theravance Biopharma logo
Theravance BiopharmaTBPH
$582K-9.5%

Other financials

Income statement

See full
Revenue$496.0M+27.0%
Gross profit$397.9M+16.6%
Operating income$18.4M-80.3%
Net income$501.0K-99.4%
EPS (diluted)$0.00-100%

Balance sheet

See full
Cash & equivalents$511.5M-1.9%
Total debt$1.6B+2,064%
Total equity$1.8B+11.3%
Total assets$4.4B+95.0%

Cash flow

See full
Operating cash flow-$165.7M-268%
CapEx$8.1M-37.4%
Free cash flow-$169.8M-291%

Valuation

See full
Market cap$8.32B+89.9%
Enterprise value$9.38B+139%
P/E125.9×+113×
P/S+2.1×

Profitability

See full
Gross margin84.6%-0.6pp
Operating margin7%-17.8pp
Net margin4%-19.2pp
FCF margin14.2%-17.6pp

Returns & leverage

See full
Return on equity3.9%-20.1pp
Debt / equity0.9×+0.8×
Current ratio2.3×-0.9×

Where this comes from

Reported directly by Alkermes in its filing.

Tagged under the XBRL concept us-gaap:InterestExpenseNonoperating.

The source filing: Alkermes’s 10-Q, filed July 28, 2026.

Filed
Jul 28, 2026, 9:22 AM EDT
Fiscal quarter
Q2 FY2026
Calendar quarter
Q2 2026
Accession
0001193125-26-319022
Line itemThree Months Ended / June 30, 2026Three Months Ended / June 30, 2025Six Months Ended / June 30, 2026Six Months Ended / June 30, 2025
OPERATING (LOSS) INCOME18,35392,978(29,927)106,770
OTHER (EXPENSE) INCOME, NET:
Interest income5,34411,09013,88321,231
Interest expense(25,925)(46,817)
Other (expense) income, net352771(941)2,327
Total other (expense) income, net(20,229)11,861(33,875)23,558
(LOSS) INCOME BEFORE INCOME TAXES(1,876)104,839(63,802)130,328
INCOME TAX PROVISION (BENEFIT)(2,377)17,7412,17720,766

Item 1. Condensed Consolidated Financial Statements:

FAQ

What is Alkermes's interest expense?
Alkermes (ALKS) reported interest expense of $25.93M in Q2 2026.
What is the long-term trend for Alkermes's interest expense?
Over 4 years (2021 to 2025), Alkermes's interest expense has grown at a 2.3% compound annual growth rate (CAGR), from $11.22M to $12.28M.
What does interest expense mean?
Cost of borrowing — interest paid or accrued on bonds, bank loans, credit facilities, finance leases, and other debt obligations.

Ask your AI about Alkermes's interest expense.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude